NCT00387647已完成2 期
A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Rate of Disease Free Survival at One Year
研究概览
简要总结
The purpose of this study is to find out if patients older than 60, with acute myeloid leukemia, who are in complete remission following initial chemotherapy, will live longer and have a lower rate of leukemia relapse when treated with azacitidine.
详细描述
Patient activity will encompass approximately 48 months: an approximate 24 month enrollment period, followed by 6 to 12 months of patient treatment. Patients will be followed for 1 year following completion of study drug treatment. During follow-up, bone marrow biopsies to confirm disease status should be obtained if peripheral blood blasts are present or if there is development of unexpected blood abnormalities to warrant suspicion of relapse, or at a minimum of every 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic confirmation of AML with greater than 20% blasts in bone marrow. All AML subtypes of the World Health Organization (WHO) classification will be included with the exception of promyelocytic leukemia and cytogenetics showing the (15;17) translocation or AML secondary to chemotherapy.
- •Achieved first morphologic complete remission (CR) or first morphologic complete remission with incomplete platelet recovery (CRp) after completion of induction chemotherapy using a standard induction regimen. Up to 2 induction cycles will be allowed. Confirmation of CR is defined as < 5% blasts in the bone marrow specimen, with a count of at least 100-200 nucleated cells and absence of Auer rods, along with peripheral blood neutrophil count >1.0 x 10^9/L and platelet count >100 x 10^9/L. Confirmation of CRp is defined as <5% blasts in the bone marrow specimen, with a count of at least 100-200 nucleated cells and absence of Auer rods, with incomplete platelet recovery (ANC ≥ 1000/µL and platelets 50-99,000/µL, along with transfusion-independence of red blood cells).
- •Received up to 2 cycles of any consolidation chemotherapy
- •Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- •Normal organ function at the time of screening: Total bilirubin ≤1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤2.5 x ULN; Serum creatinine ≤1.5 x ULN or creatinine clearance >60 mL/min for patients with creatinine levels above ULN
- •Men must agree to avoid fathering a child throughout the study.
- •Be capable of giving informed consent and have signed the informed consent form (ICF)
排除标准
- •Greater than 12 weeks since initiation of most recent cycle of consolidation chemotherapy
- •Women of childbearing potential
- •Prior relapse after complete remission for AML
- •AML secondary to previous exposure to cytotoxic chemotherapy known to induce leukemia
- •Active malignancy other than AML
- •Any diagnosis of metastatic disease
- •Have hepatic tumors
- •Radiation therapy, chemotherapy, or cytotoxic therapy, given to treat conditions other than AML <4 weeks prior to Day 1 or have not recovered from adverse events due to agents administered >4 weeks earlier
- •Known leukemic involvement of the central nervous system
- •Known or suspected hypersensitivity to azacitidine or mannitol
- •Prior or active disease that, in the opinion of the Investigator, may interfere with the procedures or evaluations to be conducted in the study (uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements)
- •Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C
- •Treatment with other investigational drugs within the 30 days prior to Day 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period
- •Any prior treatment with azacitidine or decitabine
研究组 & 干预措施
Azacitidine Treatment
Experimental
Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
干预措施: Azacitidine (Drug)
结局指标
主要结局
Rate of Disease Free Survival at One Year
时间窗: 1 year
The primary efficacy variable is disease free survival measured at one year, which is the percentage of patients who remain alive and disease free one year after the confirmation of remission by bone marrow biopsy. Relapse is defined by a bone marrow specimen with \>5% blasts or the presence of Auer rods.
次要结局
- Overall Survival (OS)(48 months)
- Number of Participants With Adverse Events(48 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT01961882Otsuka Pharmaceutical Co., Ltd.134
终止
2 期
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)LeukemiaNCT01442714Stanford University33
Unknown
不适用
Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and SurvivalAcute Myeloid LeukemiaNCT01188330Institut Paoli-Calmettes100
进行中（未招募）
1 期
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002730-21-GBCardiff University2,000
进行中（未招募）
1 期
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002730-21-DKCardiff University2,000